Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care : FDA clears Fresenius Medical Care's Novalung for treatment of acute respiratory and cardiopulmonary failure

share with twitter share with LinkedIn share with facebook
02/25/2020 | 06:19am EDT

Press Release

Fresenius Medical Care, the world's leading provider of dialysis products and services, today announced that the U.S. Food and Drug Administration (FDA) has cleared Novalung®, a heart and lung support system for the treatment of acute respiratory or cardiopulmonary failure. Novalung is the first extracorporeal membrane oxygenation (ECMO) system to be cleared for more than six hours of use as extracorporeal life support. The company expects Novalung to be available within the U.S. mid-year 2020.

Patients in acute respiratory or cardiopulmonary failure often struggle to get oxygen into their bloodstream or expel carbon dioxide out of their bodies, resulting in dangerously low levels of oxygen. This acute low oxygen state can result from a wide range of conditions.

The Novalung ECMO system pumps and oxygenates a patient's blood, reducing the stress on damaged heart and lungs. Novalung offers a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings such as intensive care units, operating rooms, cardiac catheterization labs, and emergency departments.

The use of Novalung as an ECMO device for critical care has several benefits, including minimizing the need for invasive ventilation, the ability to provide support after multi-organ injuries, and better survival outcomes for patients in cardiac arrest.

Press Photo

Novalung ECMO System

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,994 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 345,096 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Disclaimer

FMC - Fresenius Medical Care AG & Co. KGaA published this content on 25 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 February 2020 10:18:07 UTC


share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
04:32aFRESENIUS MEDICAL CARE : third-quarter net income beats on strong operations
RE
04:02aFRESENIUS SE : Jefferies maintains a Sell rating
MD
03:25aFMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies sticks Neutral
MD
02:32aFRESENIUS : 3Q Net Profit Fell Less Than Expected; Backs 2020 Outlook
DJ
02:05aFRESENIUS MEDICAL CARE : 3rd quarter results
PU
02:05aFRESENIUS MEDICAL CARE : continues solid revenue and strong earnings growth in t..
PU
02:05aFRESENIUS MEDICAL CARE : continues solid revenue and strong earnings growth in t..
EQ
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan gives a Buy rating
MD
10/26FRESENIUS SE : Buy rating from JP Morgan
MD
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from Goldman Sachs
MD
More news
Financials (USD)
Sales 2020 21 511 M - -
Net income 2020 1 549 M - -
Net Debt 2020 14 311 M - -
P/E ratio 2020 15,1x
Yield 2020 1,77%
Capitalization 23 422 M 23 437 M -
EV / Sales 2020 1,75x
EV / Sales 2021 1,64x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 97,67 $
Last Close Price 79,99 $
Spread / Highest target 43,5%
Spread / Average Target 22,1%
Spread / Lowest Target -20,5%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors